• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

ECDC: Influenza virus characterisation, Summary Europe, July 2015

tetano

tetano

Editor, Senior Moderator

Available as PDF in the following languages
EN

This document is free of charge.


Abstract
Over the course of the 2014?15 influenza season, influenza A(H3N2), A(H1N1)pdm09 and type B viruses have co-circulated in EU/EEA countries. To date, 25 EU/EEA countries have shared 1007 influenza-positive specimens with the WHO Collaborating Centre in London for detailed characterisation. Since the June 2015 report , 75 viruses have been characterised antigenically and 50 genetically.
The 27 A(H1N1)pdm09 viruses characterised antigenically were similar to the vaccine virus A/California/07/2009; all 12 characterised genetically had HA genes belonging to genetic subgroup 6B, as observed worldwide.
All 27 A(H3N2) viruses characterised by haemagglutination inhibition (HI) assay were poorly recognised (titres at least fourfold reduced compared to the homologous titre) by the reference antiserum raised against the A/Texas/50/2012 vaccine virus but relatively well recognised by antisera raised against some cell-propagated genetic subgroup 3C.3a viruses. The 341 (23 since the June 2015 report) viruses, with collection dates after 31 August 2014, characterised genetically this season fell in genetic group/subgroups 3C.3 (40), 3C.3b (76), 3C.3a (40) and 3C.2a (185). Viruses in genetic group 3C.3, excluding those in subgroup 3C.3a, were antigenically similar to reference viruses closely related to A/Texas/50/2012, while those in subgroups 3C.3a and 3C.2a were antigenically distinct.
No B/Victoria-lineage viruses were received since the June 2015 report. All 21 B/Yamagata-lineage test viruses characterised antigenically showed good reactivity with antisera raised against B/Phuket/3073/2013 (the clade 3 virus recommended for the southern hemisphere 2015 and northern hemisphere 2015?16 vaccines). Antisera raised against B/Massachusetts/02/2012 (the clade 2 virus recommended for the 2014?15 northern hemisphere season vaccine) did not recognise test viruses as well as antisera raised against B/Phuket/3073/2013. The 19 viruses characterised genetically all fell in clade 3, represented by B/Phuket/3073/2013.

http://ecdc.europa.eu/en/publicatio...=4f55ad51-4aed-4d32-b960-af70113dbb90&ID=1349
 
You must log in or register to reply here.
Back
Top